Noliprel Bi-Forte A (Indapamide, Perindopril Arginine)

Indapamide, Perindopril arginine, the active ingredients in Noliprel Bi-Forte A, constitute a combination antihypertensive presented as a tablet for oral use. This EU‑market product combines a thiazide‑like diuretic with an ACE‑inhibitor to lower blood pressure in adult patients with primary hypertension.

GNH USA supplies Noliprel Bi-Forte A as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for importers. Our global logistics network ensures timely delivery across continents.

Noliprel Bi-Forte A is indicated for hypertension, acting through combined diuretic and ACE‑inhibitor mechanisms.

- Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Isolated systolic hypertension: improves pulse‑pressure control especially in elderly individuals. - Essential (primary) hypertension: provides sustained blood pressure reduction when monotherapy is insufficient. - High‑risk hypertensive patients: contributes to cardiovascular risk reduction as part of a comprehensive treatment plan. - Hypertensive patients with peripheral edema: the diuretic component helps reduce fluid retention. - Patients requiring fixed‑dose combination therapy: simplifies dosing and may improve adherence.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Cough, often dry. - Fatigue or weakness. - Nausea or abdominal discomfort. - Electrolyte disturbances such as low potassium.

Serious or Rare Side Effects: - Angioedema or swelling of the face, lips, tongue, or throat. - Severe hypotension leading to fainting. - Acute renal impairment or rise in serum creatinine. - Hyperkalemia, particularly when combined with potassium‑sparing agents. - Hepatic dysfunction or jaundice. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome).

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium and sodium levels, especially in patients on other diuretics. - History of angioedema: avoid use in individuals with prior ACE‑inhibitor–related swelling. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; consult obstetric guidance. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Drug‑drug interactions may modify efficacy or increase toxicity.

Major Interactions (Avoid): - Aliskiren combined with an ACE inhibitor in diabetic patients: risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: thiazide component may increase lithium levels, risking toxicity. - Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood‑pressure lowering effect; monitor for hypotension. - CYP450 inhibitors (e.g., itraconazole): may increase perindopril plasma concentrations; adjust dose if needed.